Báo cáo khoa học

Key findings: Somatic mutations were determined in 96 out of 101 CRC patients. Two-thirds of the tumors harbored more than two mutations, and the most prevalent mutated genes were TP53 and APC. Among confirmed germline mutations, 10 pathogenic mutations and 11 variants of unknown significance were identified.

Được công bố tại:

Ngày đăng: 30/01/2022

Key findings: 41 pathogenic variants in 11 genes were detected in 3.2% individuals. The carrier frequency was 4.2% in people with family or personal history of cancer and 2.6% in those without history. The percentage of mutation carriers for hereditary colorectal cancer syndromes was 1.3% and for hereditary breast and ovarian cancer syndrome was 1.6%. BRCA1 and BRCA2 mutations were the most prevalent with the positive rate of 1.3% in the general cohort and 5.1% in breast or ovarian cancer patients.

Được công bố tại:

Ngày đăng: 05/01/2022

Key findings: Introduce SPOT-MAS based on combining 4 ctDNA signatures for high accuracy in early detection of CRC
AUC: 0.989; SEN 96.8%; SPEC: 97%

Được công bố tại:

Ngày đăng: 16/12/2022

Key findings: Detect ctDNA in 90.5% of the pre-operative plasma samples, whereas carcinoembryonic antigen (CEA) was elevated in only 41.3% of them.

Được công bố tại:

Ngày đăng: 12/12/2022

Key findings: Asian cohorts show higher TP53 mutation frequency than in Caucasians. Alterations in PIK3CA and PI3K signaling were dominant.

Được công bố tại:

Ngày đăng: 10/12/2022

Key findings: Evaluate SPOT-MAS performance on detection of 4 common cancer types

AUC 0.93; SEN: 73.9%; SPEC 95.9%

Được công bố tại:

Ngày đăng: 27/04/2022

Key findings:

Evaluate the combination of fragment length and mutations in early detection of HCC:
DISCOVERY: SEN: 89%; SPEC: 82%; AUC 0.88


Được công bố tại:

Ngày đăng: 21/01/2022

Key finding:

Evaluate plasma mutations as blomarkers for early detection of CRC:
SENS: 56%
SPEC: 98.95%

Được công bố tại:

Ngày đăng: 22/02/2021

Key finding:

Explore methylation signatures of 122 NSCLC patients with TKI drug resistance

Được công bố tại:

Ngày đăng: 12/08/2021

Key finding:

Identify the mutation profiles of 265 Vietnamese patients with advanced non-small cell lung cancer (NSCLC)

Được công bố tại:

Ngày đăng: 04/08/2020

Key finding: Identify cancer actionable mutations of NSCLC using plasma cfDNA

Được công bố tại:

Ngày đăng: 17/02/2020

The identification and quantification of actionable mutations are of critical importance for effective genotype-directed therapies, prognosis and drug response monitoring in patients with non-small-cell lung cancer (NSCLC)…

Được công bố tại:

Ngày đăng: 24/01/2020

Key finding: Present a novel method to detect cancer-specific mutation in blood samples of NSCLC patients

Được công bố tại:

Ngày đăng: 16/12/2019